News Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
14.23 ^USD	-3.33%		-8.31%	-11.78%

Mar. 13	Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM
Feb. 06	Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)	Apr. 18	PR
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum	Apr. 09	BU
Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM	Mar. 13
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	Feb. 27	BU
Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises	Feb. 06	MT
Transcript : Deciphera Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 06, 2024	Feb. 06
Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q4 Revenue $48.3M, vs. Street Est of $46.8M	Feb. 06	MT
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results	Feb. 06	BU
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06	CI
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 06	CI
North American Morning Briefing : Rate Doubts Keep -2-	Feb. 06	DJ
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024	Feb. 01	BU
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 01	BU
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib	Jan. 18	MT
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium	Jan. 18	BU
Deciphera Pharmaceuticals Partners With Genesis Pharma to Distribute Cancer Drug in 14 European Countries	Jan. 12	MT
GENESIS Pharma and Deciphera Pharmaceuticals, Inc. Announce an Exclusive Distribution Agreement for RIPRETINIB in 14 European Markets in Central and Eastern Europe	Jan. 12	CI
GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe	Jan. 10	AQ
Transcript : Deciphera Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	Jan. 09
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Summary

Filters